A detailed history of Teza Capital Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Teza Capital Management LLC holds 10,198 shares of RCUS stock, worth $95,963. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,198
Previous 13,693 25.52%
Holding current value
$95,963
Previous $209,000 27.75%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$14.28 - $18.44 $49,908 - $64,447
-3,495 Reduced 25.52%
10,198 $151,000
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $137,064 - $180,316
-10,012 Reduced 42.24%
13,693 $209,000
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $345,855 - $438,068
23,705 New
23,705 $361,000
Q2 2023

Feb 22, 2024

BUY
$16.97 - $22.03 $172,364 - $223,758
10,157 New
10,157 $206,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $280,089 - $363,605
16,505 New
16,505 $335,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $679M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Teza Capital Management LLC Portfolio

Follow Teza Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teza Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Teza Capital Management LLC with notifications on news.